Astellas Pharma Inc. (ALPMF)
OTCMKTS · Delayed Price · Currency is USD
12.23
0.00 (0.00%)
Dec 5, 2025, 4:00 PM EST
Astellas Pharma Employees
Astellas Pharma had 13,643 employees as of March 31, 2025. The number of employees decreased by 1,111 or -7.53% compared to the previous year.
Employees
13,643
Change (1Y)
-1,111
Growth (1Y)
-7.53%
Revenue / Employee
$993,958
Profits / Employee
$61,848
Market Cap
23.20B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 13,643 | -1,111 | -7.53% |
| Mar 31, 2024 | 14,754 | 270 | 1.86% |
| Mar 31, 2023 | 14,484 | -38 | -0.26% |
| Mar 31, 2022 | 14,522 | -933 | -6.04% |
| Mar 31, 2021 | 15,455 | -428 | -2.69% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| American Oncology Network | 1,914 |
| Glass House Brands | 374 |
| Zomedica | 152 |
| Silence Therapeutics | 116 |
| Elite Pharmaceuticals | 68 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
Astellas Pharma News
- 4 days ago - Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting - PRNewsWire
- 8 days ago - EMA Validates Review Of Astellas' PADCEV And KEYTRUDA Combination In Bladder Cancer - Nasdaq
- 17 days ago - Pfizer : FDA Oks PADCEV + Keytruda Combo For Cisplatin-Ineligible Muscle-Invasive Bladder Cancer - Nasdaq
- 4 weeks ago - Q2 2026 Astellas Pharma Inc Earnings Presentation Transcript - GuruFocus
- 4 weeks ago - Full Year 2025 Astellas Pharma Inc Earnings Presentation Transcript - GuruFocus
- 6 weeks ago - Astellas and the Internet's Favorite Grandma, Barbara 'Babs' Costello, Partner to Encourage Others to Get Ahead of Geographic Atrophy (GA) - PRNewsWire
- 6 weeks ago - Astellas Pharma Announces Encouraging Data From OPTION-VMS Phase IV Study - Nasdaq
- 6 weeks ago - Astellas Presents Preliminary Real-World VEOZAH™ (fezolinetant) Data From OPTION-VMS Phase IV Observational Study - PRNewsWire